Bristol-Myers Squibb (BMY) won approval for its oral hepatitis C virus (HCV) drug Daklinza in the European Union Wednesday, as the company continued to carve out a niche in the increasingly competitive HCV space. The EU approved Daklinza with sofosbuvir, also known as Gilead Sciences ‘ (GILD) Sovaldi, for all genotypes of the disease. This combo performed outstandingly in clinical trials, achieving a 100% cure rate in some groups. But Gilead
Big-cap biotech Gilead Sciences (GILD) was up 1% in midday trading on the stock market today, earlier touching a new high above 99, after it won a dispute with Roche over rights to its blockbuster hepatitis C drug, which separately was endorsed by the U.K.’s cost-benefit authority. Roche (RHHBY) had claimed rights to the drug, Sovaldi, last year due to its partnership with Pharmasset, which developed Sovaldi before Gilead acquired Pharmasset in
Stability is a critical determination in picking stock-watch candidates when the market is in correction. Today’s Screen Of The Day is Big Cap Leaders, companies with top-notch fundamentals and a market capitalization of at least $15 billion. The list includes well-known names and some lesser-known ones that might be undiscovered gems. Gilead Sciences (GILD), No. 1 on the Big Cap Screen list, is known for